Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Nantkwest Inc CS (NK)

Nantkwest Inc CS (NK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,552,620
  • Shares Outstanding, K 109,345
  • Annual Sales, $ 110 K
  • Annual Income, $ -92,380 K
  • 60-Month Beta 2.38
  • Price/Sales 27,858.35
  • Price/Cash Flow N/A
  • Price/Book 30.17
Trade NK with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.39
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 03/24/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.18
  • Number of Estimates 1
  • High Estimate -0.18
  • Low Estimate -0.18
  • Prior Year -0.16
  • Growth Rate Est. (year over year) -12.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.15 +40.35%
on 03/05/21
45.42 -28.47%
on 02/22/21
+4.43 (+15.79%)
since 02/09/21
3-Month
10.00 +224.90%
on 12/10/20
45.42 -28.47%
on 02/22/21
+22.22 (+216.36%)
since 12/09/20
52-Week
2.52 +1,189.29%
on 04/03/20
45.42 -28.47%
on 02/22/21
+28.09 (+638.41%)
since 03/09/20

Most Recent Stories

More News
Motus GI Appoints Experienced Financial Biotech Executive, Sonja Nelson, to its Board of Directors and as Chair of Audit Committee

FORT LAUDERDALE, Fla., June 23, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. , (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve...

MOTS : 0.0350 (-12.50%)
NK : 32.49 (+14.89%)
IBRX : 3.40 (-4.76%)
ImmunityBio and NantKwest Complete Merger

ImmunityBio , Inc. and NantKwest , Inc. ( NASDAQ: NK ), today announced the completion of their previously announced 100% stock-for-stock merger. This follows the satisfaction of all customary closing...

NK : 32.49 (+14.89%)
IBRX : 3.40 (-4.76%)
Stockholders of NantKwest Approve Merger With ImmunityBio

NantKwest, Inc . ( NASDAQ: NK ), a clinical-stage, natural killer cell-based therapeutics company, today announced that its stockholders approved by the required vote each of the proposals related to the...

NK : 32.49 (+14.89%)
ImmunityBio and NantKwest Begin Dosing Participants in Global Trials for Novel COVID-19 Vaccine; Subcutaneous Route in South Africa, Oral and Sublingual in the U.S.

ImmunityBio, Inc. , a privately-held immunotherapy company, and NantKwest, Inc. ( NASDAQ: NK ), a clinical-stage, natural killer cell-based therapeutics company, today announced the first cohorts of...

NK : 32.49 (+14.89%)
SHAREHOLDER ALERT: Barr Law Group Investigating NK, IQDNX, JELD, and MDXG; Shareholders are Encouraged to Contact the Firm

SAN DIEGO, Feb. 26, 2021 (GLOBE NEWSWIRE) -- National law firm Barr Law Group is investigating the actions of the officers and board of directors of NantKwest, Inc., Infinity Q Diversified Alpha Fund,...

NK : 32.49 (+14.89%)
JELD : 16.03 (-0.68%)
MDXG : 5.72 (-1.38%)
All Three Independent Proxy Advisory Firms – ISS, Glass Lewis and Egan-Jones – Recommend NantKwest Stockholders Vote “FOR” the Pending Merger With ImmunityBio

NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that leading independent proxy advisory firms Institutional Shareholder Services Inc. (“ISS”),...

NK : 32.49 (+14.89%)
ImmunityBio Appoints John Brennan and Wesley Clark to Board of Directors

ImmunityBio, Inc ., a privately-held immunotherapy company, today announced the appointment of John Brennan, former Central Intelligence Agency Director, and Wesley Clark, retired U.S. Army General, to...

NK : 32.49 (+14.89%)
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Merger Investigation

WILMINGTON, Del., Feb. 20, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating:

NK : 32.49 (+14.89%)
CATM : 39.01 (+0.08%)
LCYAU : 13.14 (+1.38%)
CRSA : 8.81 (-3.40%)
INVESTIGATION ALERT: Halper Sadeh LLP Investigates MDCA, CLGX, SYNC, NK; Shareholders Are Encouraged to Contact the Firm

NEW YORK, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies:

MDCA : 5.42 (-3.39%)
CLGX : 80.00 (+0.59%)
SYNC : 2.19 (-0.45%)
NK : 32.49 (+14.89%)
ImmunityBio Announces ASCO Genitourinary Cancer Symposium Presentation of Phase 2/3 Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer CIS with 71% Complete Response Rate

ImmunityBio, Inc., a privately-held immunotherapy company, today announced the oral presentation of “ Phase II/III clinical results of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive non-muscle...

NK : 32.49 (+14.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

NantKwest, Inc. is a clinical-stage immunotherapy company. The Company's product candidates include aNK, haNK and taNK for the treatment of cancers, infectious and inflammatory diseases. It is focused on harnessing the power of the innate immune system by using the natural killer cell. NantKwest, Inc....

See More

Key Turning Points

3rd Resistance Point 37.26
2nd Resistance Point 35.20
1st Resistance Point 33.85
Last Price 32.49
1st Support Level 30.44
2nd Support Level 28.38
3rd Support Level 27.03

See More

52-Week High 45.42
Last Price 32.49
Fibonacci 61.8% 29.03
Fibonacci 50% 23.97
Fibonacci 38.2% 18.91
52-Week Low 2.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar